BR112018001318A2 - composições adjuvantes lipossomais - Google Patents

composições adjuvantes lipossomais

Info

Publication number
BR112018001318A2
BR112018001318A2 BR112018001318-8A BR112018001318A BR112018001318A2 BR 112018001318 A2 BR112018001318 A2 BR 112018001318A2 BR 112018001318 A BR112018001318 A BR 112018001318A BR 112018001318 A2 BR112018001318 A2 BR 112018001318A2
Authority
BR
Brazil
Prior art keywords
liposomal adjuvant
adjuvant compositions
liposomal
outer membrane
glycolipid
Prior art date
Application number
BR112018001318-8A
Other languages
English (en)
Other versions
BR112018001318B1 (pt
Inventor
Joseph Dominowski Paul
Mwangi Duncan
K. Rai Sharath
L. Foss Dennis
K. Godbee Traci
Mary Sly Laurel
Mahan Suman
Vora Shaunak
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of BR112018001318A2 publication Critical patent/BR112018001318A2/pt
Publication of BR112018001318B1 publication Critical patent/BR112018001318B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a invenção provê uma composição adjuvante lipossomal compreendendo uma membrana externa e um compartimento interno, a membrana externa compreendendo: um composto de amônio quaternário; um esterol; um fosfolipídeo; e um glicolipídio. composições de vacina compreendendo o adjuvante lipossomal da presente invenção também são providas.
BR112018001318-8A 2015-07-20 2016-07-19 Lipossoma livre de saponina, formulação adjuvante, composição de vacina, uso terapêutico de um componente antigênico e da formulação adjuvante e método para preparar o referido lipossoma BR112018001318B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562194355P 2015-07-20 2015-07-20
US62/194,355 2015-07-20
PCT/US2016/042882 WO2017015252A1 (en) 2015-07-20 2016-07-19 Liposomal adjuvant compositions

Publications (2)

Publication Number Publication Date
BR112018001318A2 true BR112018001318A2 (pt) 2018-09-11
BR112018001318B1 BR112018001318B1 (pt) 2023-11-14

Family

ID=56555804

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018001318-8A BR112018001318B1 (pt) 2015-07-20 2016-07-19 Lipossoma livre de saponina, formulação adjuvante, composição de vacina, uso terapêutico de um componente antigênico e da formulação adjuvante e método para preparar o referido lipossoma

Country Status (28)

Country Link
EP (1) EP3325015B1 (pt)
JP (1) JP6975132B2 (pt)
KR (1) KR102085968B1 (pt)
CN (1) CN107847603B (pt)
AR (1) AR105393A1 (pt)
AU (1) AU2016297529B2 (pt)
BR (1) BR112018001318B1 (pt)
CA (1) CA2992892C (pt)
CL (1) CL2018000155A1 (pt)
CO (1) CO2018000496A2 (pt)
CY (1) CY1124319T1 (pt)
DK (1) DK3325015T3 (pt)
ES (1) ES2878475T3 (pt)
HK (1) HK1250338A1 (pt)
HR (1) HRP20210872T1 (pt)
HU (1) HUE054422T2 (pt)
LT (1) LT3325015T (pt)
MX (1) MX2018000879A (pt)
PH (1) PH12018500146A1 (pt)
PL (1) PL3325015T3 (pt)
PT (1) PT3325015T (pt)
RS (1) RS62015B1 (pt)
RU (1) RU2736642C2 (pt)
SI (1) SI3325015T1 (pt)
TW (1) TWI655002B (pt)
UA (1) UA125017C2 (pt)
WO (1) WO2017015252A1 (pt)
ZA (1) ZA201800285B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202206098A (zh) * 2020-08-11 2022-02-16 美商碩騰服務公司 抗冠狀病毒疫苗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3521994A1 (de) * 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5556637A (en) * 1990-08-06 1996-09-17 A. Nattermann & Cie. Gmbh Water containing liposome system
EP0979100A1 (fr) * 1997-04-30 2000-02-16 Merieux OraVax SNC COMPOSITION VACCINALE ANTI-$i(HELICOBACTER) COMPRENANT UN ADJUVANT DE TYPE TH1
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
US7749520B2 (en) * 2004-07-07 2010-07-06 Statens Serum Institut Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids
PT1765289E (pt) * 2004-07-07 2008-12-05 Statens Seruminstitut Composições e processos para estabilizar formulações de adjuvantes à base de lípidos por meio de glicolípidos
MY159370A (en) * 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
WO2007085962A2 (en) * 2006-01-26 2007-08-02 Pfizer Products Inc. Novel glycolipid adjuvant compositions
KR101333852B1 (ko) * 2008-06-27 2013-11-27 조에티스 엘엘씨 신규한 면역증강 조성물
DK2424562T3 (en) 2009-04-30 2015-12-07 Coley Pharm Group Inc Pneumococcal vaccine and uses thereof
MX2012002639A (es) * 2009-09-03 2012-03-14 Pfizer Vaccines Llc Vacuna de pcsk9.
LT2575878T (lt) * 2010-05-28 2018-11-12 Zoetis Belgium S.A. Vakcinos, apimančios cholesterolio ir cpg, kaip vienintelio adjuvanto-nešiklio, molekules
WO2013004234A2 (en) * 2011-07-04 2013-01-10 Statens Serum Institut Methods for producing liposomes
CN102973506B (zh) * 2011-09-05 2015-06-03 中国科学院深圳先进技术研究院 阳离子脂质体及其制备方法
HRP20211452T1 (hr) * 2013-05-14 2021-12-24 Zoetis Services Llc Novi cjepivni pripravci koji sadrže imunostimulacijske oligonukleotide
BR112016005948A2 (pt) * 2013-09-19 2017-09-26 Zoetis Services Llc adjuvantes com base em óleo
FR3012964A1 (fr) * 2013-11-12 2015-05-15 Seppic Sa Vaccins adjuves pour vaccination aviaire in ovo

Also Published As

Publication number Publication date
SI3325015T1 (sl) 2021-08-31
HK1250338A1 (zh) 2018-12-14
UA125017C2 (uk) 2021-12-29
CO2018000496A2 (es) 2018-04-19
CA2992892C (en) 2019-12-31
CY1124319T1 (el) 2022-07-22
PT3325015T (pt) 2021-07-08
RS62015B1 (sr) 2021-07-30
HUE054422T2 (hu) 2021-09-28
LT3325015T (lt) 2021-08-10
JP2018524388A (ja) 2018-08-30
CN107847603A (zh) 2018-03-27
AU2016297529B2 (en) 2021-09-09
AU2016297529A1 (en) 2018-02-01
KR20180025977A (ko) 2018-03-09
NZ739040A (en) 2021-06-25
DK3325015T3 (da) 2021-07-05
EP3325015B1 (en) 2021-05-12
MX2018000879A (es) 2018-05-15
RU2018102114A (ru) 2019-08-20
JP6975132B2 (ja) 2021-12-01
WO2017015252A1 (en) 2017-01-26
RU2736642C2 (ru) 2020-11-19
ZA201800285B (en) 2019-07-31
CN107847603B (zh) 2021-05-11
CA2992892A1 (en) 2017-01-26
RU2018102114A3 (pt) 2019-12-23
ES2878475T3 (es) 2021-11-18
TWI655002B (zh) 2019-04-01
BR112018001318B1 (pt) 2023-11-14
HRP20210872T1 (hr) 2021-07-09
PL3325015T3 (pl) 2021-10-25
CL2018000155A1 (es) 2018-06-08
KR102085968B1 (ko) 2020-03-06
EP3325015A1 (en) 2018-05-30
PH12018500146A1 (en) 2018-07-23
AR105393A1 (es) 2017-09-27
TW201711675A (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
EP3728568A4 (en) METHODS AND COMPOSITIONS FOR DELIVERING VIRAL VECTORS BY THE BLOOD-BRAIN BARRIER
BR112018067538A2 (pt) inibidores de ire1-alfa de pequenas moléculas
EP3426258A4 (en) CATIONIC STEROIDAL ANTIBIOTIC COMPOSITIONS FOR THE TREATMENT OF SKIN TISSUE
WO2017106957A8 (en) Lipid-linked prodrugs
BR112017012679A2 (pt) compostos imunomoduladores, seus usos, composição e kit
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
EA201890052A1 (ru) Регуляторы nrf2
EP3509581A4 (en) FORMULATIONS OF (R
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
CL2018001192A1 (es) Análogos de saponina triterpeno
CY1123574T1 (el) Αντιπολλαπλασιαστικες ενωσεις και φαρμακευτικες συνθεσεις και χρησεις αυτων
EP3523274A4 (en) FORMULATIONS FOR THE ADMINISTRATION OF EFLORNITHIN
CO2019002523A2 (es) Inhibidores de dopamina–β–hidroxilasa penetrantes de la barrera hematoencefálica
MX2017003794A (es) Formulaciones estables de lipidos y liposomas.
EP3510992A4 (en) SKIN-CREAMING COMPOSITION WITH MANNOSYL ETHYTROLIPOLIDE
ECSP17074919A (es) Piroglutamato de vortioxetina
EP3827842A4 (en) COMPOSITION CONTAINING AN INFLUENZA VACCINE
BR112017017930A2 (pt) o-oligossacaril-transferases de acinetobacter e usos das mesmas
EP3401379A4 (en) TWO-PIECE ADHESIVE COMPOSITION ON URETHANE BASE FOR MOTOR VEHICLES
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
EP3441080A4 (en) PHARMACEUTICAL COMPOSITION FOR HEALING WOUNDS CONTAINING SUBSTANCE P
EP3688033A4 (en) NEW FORMULATIONS THAT STABILIZE LOW DOSE ANTIBODY COMPOSITIONS
EP3618841A4 (en) EYEBLE APPLICATIONS OF MATRIX-RELATED VESICLES (MBVS)
EP3373909A4 (en) LIPID EMULSION FORMULATIONS ENRICHED WITH VITAMIN K FOR THE TREATMENT OF PHARMACEUTICAL TOXICITY
BR112018001318A2 (pt) composições adjuvantes lipossomais

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/07/2016, OBSERVADAS AS CONDICOES LEGAIS